CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most Promising Private Companies
Award Presented at AdvaMed 2012: The MedTech Conference
PALO ALTO, Calif. – Oct. 2, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company has been named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world. FierceMedicalDevices editors chose this year's winners based on their top management teams, notable financial backing, promising technologies and market opportunities. The award was presented today at an event that took place during AdvaMed 2012: The MedTech Conference in Boston, Mass.
“CardioDx was chosen as one of the Fierce 15 based, in part, on its creativity and innovation. The company has paired cutting-edge science with a huge unmet need, and Corus CAD has wowed clinicians, payers and investors alike,” said FierceMedicalDevices Editor Damian Garde.
“We are honored to be included in FierceMedicalDevices’ inaugural list of the most promising privately held companies in our industry today,” said David Levison, president and CEO of CardioDx. “The value of Corus CAD as a means to reducing unnecessary cardiovascular procedures and radiation exposure for patients is being increasingly recognized by clinicians, with more than 30,000 tests ordered to date. The favorable Medicare coverage decision we recently received further validates the clinical and economic benefits of Corus CAD to patients and the healthcare system.”
With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient’s symptoms are due to obstructive coronary artery disease (CAD), enabling many patients to avoid unnecessary invasive procedures and exposure to imaging-related radiation risks or imaging agent intolerance. The test has been clinically validated in multiple independent patient cohorts, including two prospective, multicenter U.S. studies, PREDICT and COMPASS. Additionally, a retrospective, multicenter chart review study and the prospective IMPACT trial at Vanderbilt University demonstrated that Corus CAD use yields statistically significant and clinically relevant changes in patient management decisions in both primary care and cardiology settings.
CardioDx recently announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the Corus CAD gene expression test for the evaluation of patients presenting with typical and atypical symptoms suggestive of coronary artery disease. With this decision, the Corus CAD gene expression test is now a covered benefit for more than 40 million Medicare enrollees in the U.S.
Corus CAD has also been recognized by The Wall Street Journal’s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME’s Top Ten Medical Breakthroughs.
An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on clinical studies, FDA/EMEA regulations, and postmarketing. A complete list of "Fierce 15" companies is available online at www.fiercemedicaldevices.com.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.
Media Contact: Nicole Osmer